Lista de obras - Giorgio Valabrega - Dominio Público Uruguay

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

artículo científico publicado en 2018

A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients

artículo científico publicado en 2015

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

artículo científico

Adoptive immunotherapy against ovarian cancer

artículo científico publicado en 2016

Androgen receptor status predicts development of brain metastases in ovarian cancers.

artículo científico publicado en 2017

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

artículo científico publicado en 2019

Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer

artículo científico publicado en 2015

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

scientific article published on 11 June 2019

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.

artículo científico publicado en 2017

Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.

artículo científico publicado en 2006

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer ⬇️

artículo científico publicado el 1 de octubre de 2012

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience

scientific article published on 10 August 2020

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications

scientific article published on 19 November 2019

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

artículo científico publicado en 2003

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

artículo científico publicado en 2010

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

artículo científico publicado en 2011

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.

artículo científico publicado en 2011

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

artículo científico publicado en 2016

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

artículo científico publicado en 2020

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?

artículo científico publicado en 2022

Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups

artículo científico publicado en 2020

Metastatic breast cancer subtypes and central nervous system metastases

artículo científico publicado en 2014

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

artículo científico publicado en 2019

Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer

artículo científico publicado en 2012

Multitarget drugs: the present and the future of cancer therapy

artículo científico publicado en 2009

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.

artículo científico publicado en 2016

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

scientific article published on 04 November 2019

Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

artículo científico publicado en 2012

Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.

artículo científico publicado en 2018

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

artículo científico publicado en 2006

Ovarian Cancer Immunotherapy: Turning up the Heat

scientific article published on 15 June 2019

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

artículo científico publicado en 2014

PARP Inhibitors in Ovarian Cancer.

artículo científico publicado en 2018

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

artículo científico publicado en 2013

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

artículo científico publicado en 2012

Recent advances in the development of breast cancer vaccines

artículo científico publicado en 2014

Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

artículo científico publicado en 2018

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

artículo científico publicado en 2008

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. ⬇️

artículo científico publicado en 2019

Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

artículo científico publicado en 2010

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

artículo científico publicado en 2005

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

artículo científico publicado en 2019

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.

artículo científico publicado en 2015

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

scientific article published on 09 April 2019

Translational Research in Ovarian Cancer

scientific article published on 08 December 2020

Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities ⬇️

artículo científico publicado el 10 de marzo de 2011

Trastuzumab beyond disease progression: case closed?

artículo científico publicado en 2009

Trastuzumab treatment in breast cancer

scientific article published on 01 May 2006

Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial

artículo científico publicado en 2008

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

artículo científico publicado en 2007

Underuse of anthracyclines in women with HER-2+ advanced breast cancer

artículo científico publicado en 2010

Veliparib: a new therapeutic option in ovarian cancer?

scientific article published on 10 May 2019

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

artículo científico publicado en 2008

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

scientific article published on 01 November 2019

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

artículo científico publicado en 2016

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy

artículo científico publicado en 2015

Lista de obras de Giorgio Valabrega

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

Adoptive immunotherapy against ovarian cancer

Androgen receptor status predicts development of brain metastases in ovarian cancers.

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.

Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer ⬇️

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?

Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups

Metastatic breast cancer subtypes and central nervous system metastases

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer

Multitarget drugs: the present and the future of cancer therapy

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

Ovarian Cancer Immunotherapy: Turning up the Heat

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

PARP Inhibitors in Ovarian Cancer.

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

Recent advances in the development of breast cancer vaccines

Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. ⬇️

Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

Translational Research in Ovarian Cancer

Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities ⬇️

Trastuzumab beyond disease progression: case closed?

Trastuzumab treatment in breast cancer

Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

Underuse of anthracyclines in women with HER-2+ advanced breast cancer

Veliparib: a new therapeutic option in ovarian cancer?

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy